ORIGINAL RESEARCH ARTICLE ORIGINAL RESEARCH ARTICLE BACKGROUND: Abnormal amino acid metabolism is associated with vascular disease. However, the causative link between dysregulated tryptophan metabolism and abdominal aortic aneurysm (AAA) is unknown.
A
bdominal aortic aneurysm (AAA) is a permanent, localized dilation of the abdominal aorta. It occurs in up to 9% of adults >65 years of age, with ≈15 000 annual deaths after rupture in the United States. 1, 2 Pathologically, AAA is characterized by a dilatation of all layers of the arterial wall attributable to elastin loss, smooth muscle cell apoptosis, and compensatory collagen deposition. [3] [4] [5] Currently, no therapeutic strategies are proven to block AAA progression and rupture, and endovascular or open surgical repair appears to be the only available approach. 2 Despite decades of research on AAA, there is a paucity of knowledge on the mechanisms and factors controlling AAA growth. Therefore, elucidating the molecular basis for this disease is imperative for the development of novel pharmacological therapies.
The kynurenine (Kyn) pathway contributes to several fundamental biological processes and is the major route for the metabolism of essential amino acid tryptophan (Trp). Trp is constitutively oxidized by tryptophan 2,3-dioxygenase in liver cells. In other cell types, Trp is catalyzed by an alternative inducible indoleamine-pyrrole 2,3-dioxygenase (IDO) under certain pathophysiological conditions. 6 The first stable intermediate from the Kyn pathway is Kyn. Subsequently, in eukaryotes, kynureninase (KNU) directly catalyzes the hydrolysis of Kyn or 3-hydroxykynurenine (3-HK) to form anthranilic acid or 3-hydroxyanthranilic acid (3-HAA), respectively. 7, 8 Catabolites in the Kyn pathway of Trp metabolism play critical roles in vascular physiology and pathology 9, 10 in addition to regulating the immune system 11, 12 and inflammation. 6, 13 Moreover, IDO is a potential novel contributor to vessel relaxation in systemic infections, 14, 15 which are also activated in acute severe heart attacks. 16 Recently, IDO was reported to play a critical role in atherogenesis in mice. 17, 18 All these findings have illustrated the key role of the Kyn pathway in the increased prevalence of cardiovascular disease (CVD). 19 However, whether catabolites from the Kyn pathway contribute to AAA is unknown.
Angiotensin II (AngII) is a principal mediator for the development and progression of AAA. 20 Many elements of human AAA are recapitulated in AngII-infused mice. 21 Our previous study demonstrated that AngII infusion powerfully induces IDO expression and increases Kyn metabolites of Trp in the aortas of mice. 10 More importantly, IDO deletion significantly inhibits AngIItriggered nicotinamide adenine dinucleotide phosphate-derived oxidative stress in vessels. 10 Therefore, we sought to identify the roles of the Kyn pathway and its catabolites in AngII-induced AAA. AAA formation in AngII-treated apolipoprotein e-deficient (Apoe -/-) mice was significantly prevented in the IDO-deficient (IDO -/-) background and under the condition of in vivo KNU short-interfering RNA (siRNA) transfection. Mechanistically, the genetic inhibition of IDO and KNU substantially eliminated 3-HAA, which was the key Trp catabolite of the AngII-induced Kyn pathway, and intensely promoted matrix metallopeptidase (MMP)-2 expression controlled by nuclear factor κB (NF-κB) transcription factor in vascular smooth muscle cells (VSMCs).
METHODS
All procedures involving animals were approved by the Institutional Animal Care and Use Committee at the University of Oklahoma Health Sciences Center and Georgia State University. Human aortic samples used in this study were procured at Peking Union Medical College following patient consent according to institutional review board-approved protocol.
IDO -/-mice were crossed with Apoe -/-mice to generate Apoe -/-/IDO -/-mice. Apoe -/-and Apoe -/-/IDO -/-mice at age 8 weeks or 4 weeks after bone marrow transplantation or with KNU siRNA transfection on a chow diet were infused with AngII (1000 ng/kg per min) or physiological saline (0.9% sodium chloride) infusion for 4 weeks or intraperitoneally injected with 3-HAA (200 mg/kg/d) or vehicle for 6 weeks.
Detailed descriptions of other unmentioned materials, methods, and experimental procedures are available in the Materials and Methods of the online-only Data Supplement.
Statistical Analyses
All statistical analyses were performed by using GraphPad Prism 6. Quantitative results are reported as means±SEMs.
Clinical Perspective
What Is New?
• For the first time, we established a causative link between dysregulated tryptophan metabolism and abdominal aortic aneurysm (AAA), a life-threatening vascular disease in vivo.
• 3-Hydroxyanthranilic acid, a key tryptophan catabolite of the angiotensin II-induced AAA in vascular smooth muscle cells, was responsible for angiotensin II-induced AAA in vivo.
• 3-Hydroxyanthranilic acid-activated nuclear factor-κB transcription factor promoted matrix metallopeptidase 2 expression in vascular smooth muscle cells.
• Human AAA samples had stronger staining with the antibody against 3-hydroxyanthranilic acid than those in adjacent nonaneurysmal aortic sections of human AAA samples.
What Are the Clinical Implications?
• The identification of 3-HAA in angiotensin II-triggered AAA and in human patients with AAA suggests that tryptophan-derived metabolites might be a biomarker for AAA diagnosis.
• The agents that alter tryptophan metabolism may have therapeutic potentials for preventing or treating AAA. 
RESULTS

IDO Deletion Abrogates AngII-Induced AAA Formation
Recently, AngII-induced mouse AAA formation in the hypercholesterolemic mouse strain (Apoe −/− ) has become the most widely used model. [22] [23] [24] [25] To unravel the role of the Trp-Kyn pathway in AAA formation, we generated Apoe -/-/IDO -/-(double-knockout) mice and detected the outcome of a 4-week AngII infusion (1000 ng/min per kg) in Apoe -/-and Apoe -/-/IDO -/-mice. As depicted in Tables I and II in the online-only Data Supplement, AngII infusion increased blood pressure without affecting the heart rate or any metabolic parameters. Morphologically, the aortas of saline-infused Apoe -/-/IDO -/-mice did not differ from those of saline-infused control Apoe -/-mice ( Figure 1A ). In line with previous reports, 3,4,26 the incidence of AngII-induced AAA in Apoe -/-mice was 73% ( Figure 1A and 1B) . Both the maximal abdominal aortic diameter ( Figure 1C ) and total aortic weight ( Figure 1D ) were significantly higher in AngII-infused Apoe -/-mice than in saline-infused mice. Furthermore, the frequent disruption and increased degradation of elastic laminas were observed in AngII-infused Apoe -/-mice but not in saline-infused mice ( Figure 1E and 1F) . Markedly increased collagen deposition was also observed in AngII-infused Apoe -/-mice ( Figure 1E and 1G ). In contrast, only 15% of AngII-infused Apoe -/-/IDO -/-mice developed AAA ( Figure 1A and 1B) . The maximal abdominal aortic diameter ( Figure 1C ) and total aortic weight ( Figure 1D) confers protection from AngII-induced AAA formation in Apoe -/-mice in vivo.
IDO Deficiency Mitigates MMP2 Upregulation in AAA Mice
AngII infusion is intensely associated with vascular inflammation, which is considered a key mediator of AngII-induced AAA formation. 25, 26 As shown in Table  III in the online-only Data Supplement, serum concentrations of inflammatory cytokines, including interferon (IFN)-γ, tumor necrosis factor-α, interleukin-6, and cyclophilin A, were elevated in both AngII-infused Apoe Figure 2D ). This may be because of the high content of Trp in mouse diets.
MMPs play a key role in the initiation and progression of AAA. 27 In particular, VSMC-derived MMP2 28, 29 and macrophage-derived MMP9 30 are critical for AAA development. Thus, we next determined if IDO deletion affects the levels of MMP2 and MMP9 in AngII-induced AAA formation. MMP2 mRNA levels ( Figure 2F and Figure IA in the online-only Data Supplement), protein expressions ( Figure 2A , 2B, and 2E), and activity ( Figure 2F ) were substantially increased in AngII-infused Apoe -/-mice. In contrast, the increases in MMP2 expression and activity were dramatically abrogated in the aortas of AngII-infused IDO -/-mice ( Figure 2A , 2B, 2E, and 2F). However, IDO deletion did not alter the AngII-induced increase in MMP9 activity ( Figure 2F ). Therefore, MMP2 seems to be the most predominant MMP inhibited by IDO deletion in AngII-induced AAA formation.
Vascular IDO Deletion Inhibits AAA Formation
Based on the data presented here, we postulated that the activation of the Kyn pathway in VSMCs promotes AAA formation. To test this hypothesis, we performed 31 and to halt cell cycle progression in T cells. 32 However, no reductions in Trp were observed in AngII-infused Apoe -/-mice ( Figure 2D ). Therefore, different concentrations of exogenous Trp were supplemented in the culture medium of HASMCs with IFN-γ treatment for 48 hours to mimic the in vivo environment. MMP2 expression was markedly upregulated in HASMCs exposed to IFN-γ and >40 μmol/L Trp ( Figure  IIIB Hypertryptophanemia [33] [34] [35] is a rare autosomal recessive metabolic disorder that results in a massive buildup of Trp in the blood. 36, 37 The addition of 500 μmol/L Trp 
3-HAA Promotes NF-κB-Mediated MMP2 Expression in HASMCs
To identify Kyn pathway catabolites that upregulate MMP2, the expression and activity of MMP2 were detected in HASMCs incubated with major exogenous metabolites 6, 37 of Trp degradation. A dramatic increase in MMP2 expression and activity was observed with 3-HAA, [38] [39] [40] [41] but not with Kyn, 10 3-HK, 10 kynurenic acid, 42 anthranilic acid, 43 xanthurenic acid, 44 or quinolinic acid (QA) 45 ( Figure 5A ). Furthermore, the expression and activity of MMP2 induced by 3-HAA appeared to be in a concentration-and time-dependent manner ( Figure IVA and IVB in the online-only Data Supplement).
Following its synthesis by IDO in certain cell types, Kyn can be further metabolized by kynurenine-3-monooxygenase into 3-HK, which is catabolized by KNU to form 3-HAA. 6 To further validate the effects of 3-HAA on MMP2 induction in VSMCs, we detected endogenous 3-HAA and the expression of KNU. Intracellular 3-HAA and KNU expression emerged in IFN-γ-treated, Trp-supplemented HASMCs, along with MMP2 elevation (Figure 5B through 5D ). Accordingly, IDO or KNU knockdown blocked endogenous 3-HAA formation ( Figure 5B and 5C), which resulted in the inhibition of MMP2 expression and activity induced by IFN-γ with additional Trp (Figure 5D ). These results suggest that Trp-derived 3-HAA upregulates MMP2 expression in HASMCs in vitro.
Gene enrichment and positive immunostaining of NF-κB p65 and p50 have been observed in AAA tissues, 46 and the modulation of NF-κB on MMP2 gene expression in vascular endothelium has been studied, as well. 47 We also observed 3-HAA-induced NF-κB p65 phosphorylation in HASMCs ( Figure 5F ). Furthermore, NF-κB p65 knockdown in HASMCs by specific siRNA followed by 3-HAA treatment for 24 hours clearly blocked the elevation of MMP2 mRNA ( Figure 5E ) and protein triggered by 3-HAA, and 3-HAA-accelerated MMP2 activity, as well ( Figure 5E and 5F ). These results demonstrate that NF-κB is implicated in 3-HAA-induced MMP2 upregulation.
IDO Deletion Abolishes 3-HAA Generation in AAA Mice
Next, we detected endogenous 3-HAA in vivo. In line with our in vitro data, increased levels of 3-HAA were observed in the aortas of AngII-treated Apoe -/-mice, but not in those of Apoe -/-/IDO -/-mice ( Figure 6A and 6B). Plasma 3-HAA levels were notably raised in AngIItreated Apoe -/-mice ( Figure 6C ), suggesting that IDO 
3-HAA Accelerates MMP2 Expression in Mouse Aortas
To ascertain the effect of 3-HAA in MMP2 expression in vivo, Apoe -/-and Apoe 
KNU Deficiency Attenuates AngIIInduced AAA Formation
To further identify the effects of endogenous 3-HAA on AAA development, we treated AngII-infused Apoe -/-mice with KNU siRNA. There were no differences in blood pressure or heart rate between scrambled siR-NA-and KNU siRNA-transfected, AngII-infused mice (Table V in the online-only Data Supplement). Changes in metabolic parameters were also not observed (Table  VI in /IDO -/-mice were treated with vehicle or 400 μmol/L 3-HAA for 48 hours ex vivo. MMP2 and GAPDH mRNA were detected by RT-PCR, MMP2 and β-actin protein expressions in the aortas were detected by immunoblotting, and MMP2 activity in the aortas and supernatants was detected by zymography. All results were obtained from 8 mice in each group. P values in B, C, E, and F were obtained by a 2-way ANOVA with following Bonferroni multiple comparisons. The error bars in B, C, E, and F are SEM. AngII indicates angiotensin II; DMSO, dimethyl sulfoxide; 3-HAA, 3-hydroxyanthranilic acid; HPLC, high-performance liquid chromatography; IDO, indoleamine 2,3-dioxygenase; MMP2, matrix metallopeptidase 2; and RT-PCR, real-time polymerase chain reaction. ORIGINAL RESEARCH ARTICLE developed AAA in comparison with a 75% incidence of AAA in AngII-infused, scrambled siRNA-transfected Apoe -/-mice ( Figure 7A and 7B). The maximal abdominal aortic diameter ( Figure 7C ) and total aortic weight ( Figure 7D ) were remarkably lower in mice with KNU knockdown. Moreover, AngII infusion did not cause significant elastic lamina degradation and aortic expansion in KNU siRNA-transfected Apoe -/-mice ( Figure 7E  and 7F ). Collagen deposition was dramatically reduced in KNU siRNA-transfected mice in comparison with control mice (Figure 7E and 7G) . These results suggest that KNU knockdown protects Apoe -/-mice from AngIIinduced AAA formation in vivo.
Inhibition of Trp-Derived 3-HAA Abolishes MMP2 Upregulation in AAA Mice
As shown in Table VII in the online-only Data Supplement, KNU silencing did not alter serum concentrations of inflammatory cytokines in AngII-infused Apoe -/-mice. Accordingly, both IFN-γ and IDO expression levels were markedly enhanced in the aortas of AngII-treated Apoe -/-mice with or without KNU knockdown (Figure 8D and Figure VA and VB in the online-only Data Supplement). As expected, AngII only increased KNU expression in Apoe -/-mice transfected with scrambled siRNA ( Figure 8A, 8B, and 8D ). In line with this, high plasma levels of Kyn were detected in both groups of mice ( Figure VD in the online-only Data Supplement), whereas high 3-HAA levels were observed only in the plasma ( Figure 8C ) and aortas ( Figure 8A and 8B) of AngII-treated Apoe -/-mice with scrambled siRNA but not in KNU siRNA-transfected Apoe -/-mice. Because of compensatory Trp in the mouse diet, no differences in plasma Trp levels were found between scrambled siR-NA-and KNU siRNA-transfected mice ( Figure VC in the online-only Data Supplement).
Next, we determined whether KNU silencing affects MMP2 levels in AngII-induced AAA formation. In comparison with AngII-infused and scrambled siRNA-transfected Apoe -/-mice, MMP2 mRNA levels ( Figure 8E and Figure ID in the online-only Data Supplement), protein expressions ( Figure 8A , 8B, and 8D), and activity (Figure 8E) were significantly reduced in AngII-infused, KNU siRNA-transfected Apoe -/-mice, indicating that an endogenous 3-HAA reduction lowers MMP2 expression to inhibit AAA formation.
Kynurenine Pathway Activation in Human AAA Formation
To establish the clinical relevance of Kyn pathway activation and AAA formation, we further examined the expression of Kyn pathway key enzymes IDO and KNU in human AAA samples. Human AAA tissues and their control adjacent aortic sections without an aneurysm were obtained from patients undergoing open surgery. As expected, proaneurysmal molecules, such as MMP2, were dramatically elevated in human AAA sections in comparison with adjacent nonaneurysmal aortic sections ( Figure 8F and 8G) . Importantly, both IDO1 and KNU were significantly upregulated in human AAA samples ( Figure 8F and 8G) . Moreover, human AAA samples had stronger anti-3-HAA staining than adjacent nonaneurysmal aortic sections (Figure 8H and 8I) .
DISCUSSION
This study is the first to show that IDO deletion or KNU knockdown in vivo restrained AngII-induced AAA in Apoe -/-mice. In VSMCs, AngII-mediated IFN-γ induced the expression of IDO and KNU, which are 2 key enzymes that regulate 3-HAA formation in the Kyn pathway of Trp metabolism. Elevated 3-HAA upregulated NF-κB p65 phosphorylation at Ser536, resulting in the aberrant expression and activation of MMP2 and consequent extracellular matrix degradation ( Figure VI in the online-only Data Supplement). This mechanism not only provides an evident link between the Trp-Kyn pathway and AAA but also identifies a specific Trp metabolite (3-HAA) that promotes AAA formation.
Activation of the Kyn pathway by AngII triggered AAA formation in Apoe -/-mice, and either IDO or KNU inhibition had a remarkably protective effect. These results might provide further insight into the emerging role of the Kyn pathway in the prevalence of CVD. Positive correlations between increased kynurenines (Kyn, 3-HK, 3-HAA, kynurenic acid, anthranilic acid, or QA) and oxidative stress, immunoinflammatory responses, or endothelial dysfunction in CVD have been shown. [48] [49] [50] [51] [52] [53] In addition, Kyn, QA, and MMPs were significantly higher in patients undergoing continuous peritoneal dialysis with CVD than in patients without CVD and controls. 52 QA and the QA/Kyn ratio have been identified to be factors that are independently associated with MMP2, and QA is positively correlated ORIGINAL RESEARCH ARTICLE with MMP2. 52 Furthermore, Kyn increases MMP1 and MMP3 in dermal fibroblasts. 54 These observations support our findings for the direct connection between Kyn pathway activation and upregulated MMPs.
VSMCs are essential for AngII-induced AAA formation. 3, 4 Regarding the dominant MMPs (MMP2 and MMP9) in vascular tissue, 55 our results show that IDO deletion did not affect AngII-induced MMP9 but significantly reduced AngII-induced MMP2, which is exclusively secreted by VSMCs. The bone marrow transplantation experiments validated that vascular cells were the key targets of Kyns in the initiation and progression of AAA. Similar findings were observed in cultured HASMCs. Treatment with IFN-γ, along with the addition of exogenous Trp, induced MMP2 activation in vitro. The additional Trp not only rectified Trp depletion in the presence of IFN-γ but also dramatically augmented the cascade of Kyn generation in HASMCs.
Most important, we identified the specific product of Trp metabolism that is responsible for AngII-induced AAA. Exogenous 3-HAA treatment increased the mRNA and protein expressions of MMP2 in HASMCs in vitro and in mouse aortas in vivo, and MMP2 activity, as well. Subsequently, NF-κB mediated 3-HAA-instigated MMP2 induction in HASMCs in vitro. As a product of 3-HK, 3-HAA is prone to auto-oxidation in a process that favors the formation of superoxide anions. 56 In experimental models, the pattern of 3-HAA in mitochondrial processes involves the inhibition of oxygen uptake by mitochondrial respiration with nicotinamide adenine dinucleotide-dependent substrates, uncoupling of the respiratory chain, and oxidative phosphorylation. 57 In patients with chronic kidney disease, 3-HAA is independently associated with monocyte chemoattractant protein-1 and macrophage inflammatory protein-1β. 58 In addition, 3-HAA induces the depletion of intracellular glutathione in activated T cells without increasing formation of reactive oxygen species. 59 The results from these studies provide us with the background needed to conduct further studies about 3-HAA-mediated VSMC activation and MMP2 secretion. 3-HAA might promote VSMC senescence with or without reactive oxygen species generation. It has also been shown to inhibit atherosclerosis by regulating lipid metabolism and inflammation, and can significantly decrease plasma cholesterol and triglyceride levels in low-density lipoprotein receptor-deficient mice.
38,39 However, we did not observe any decreases in lipid levels in 3-HAAtreated Apoe -/--mice. Results from the current study have shed light on the role of endogenous 3-HAA in AngII-induced AAA. Both in vitro and in vivo KNU silencing substantially lessened MMP2 activation in VSMCs. The in vivo silencing of KNU eliminated AngII-induced AAA development in Apoe -/-mice. Our investigation into the effects of exogenous and endogenous 3-HAA on MMP2 upregulation in VSMCs has clarified the role of 3-HAA in AngIIinduced AAA.
Overall, we have established a causative correlation between Kyn pathway activation and AAA formation in vivo and identified the contribution of 3-HAA in AngII-triggered AAA. The identification of 3-HAA in AngII-triggered AAA and in human patients with AAA suggests that Trp-derived metabolites might be a biomarker for AAA diagnosis, and the agents that prevent 3-HAA generation may have therapeutic potential for AAA and other CVDs.
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